Peter Lomedico

The JDRF T1D Fund (www.t1dfund.org) is a venture philanthropy fund accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D) through catalytic commercial investments. Through its investments in partnership with private capital, including venture capital, corporations and foundations, the T1D Fund seeks to attract the private investment necessary to advance drugs, devices, diagnostics, and vaccines into the hands of those living with T1D. The T1D Fund invests in areas strategically aligned with JDRF, the leading global organization funding T1D research, with an exclusive focus on supporting the best commercial opportunities. The T1D Fund will reinvest any realized gains into new investments to further its mission. Before joining the T1D Fund in 2017, Peter Lomedico spent 11 years working with JDRF Research to establish T1D research collaborations with biotechnology and pharmaceutical companies. Peter has a diverse background in molecular biology, diabetes research and drug discovery, before JDRF he worked at several biotechnology companies (NeoGenesis, CuraGen and Genome Therapeutics) and ran drug discovery and development projects at Hoffmann-La Roche in NJ and Switzerland. Early in his career, Peter conducted diabetes research as a grad student and was a JDRF postdoctoral fellow at Harvard University. He has more than 30 publications and three issued patents. Peter serves on the board for AnTolRx, Inc., a T1D Immunology company spun off from Harvard Medical School with a JDRF equity investment. Peter has a Ph.D. in molecular biology from the University of Texas Health Science Center at Houston and a B.S. in biology from Villanova University.